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Glucocorticoids are a class of steroid hormones derived from cholesterol. Their actions 
are mediated by the glucocorticoid and mineralocorticoid receptors, members of the 
superfamily of nuclear receptors, which, once bound to their ligands, act as transcription 
factors that can directly modulate gene expression. Through protein–protein interactions 
with other transcription factors, they can also regulate the activity of many genes in a 
composite or tethering way. Rapid non-genomic signaling was also demonstrated since 
glucocorticoids can act through membrane receptors and activate signal transduction 
pathways, such as protein kinases cascades, to modulate other transcriptions factors 
and activate or repress various target genes. By all these different mechanisms, gluco-
corticoids regulate numerous important functions in a large variety of cells, not only in 
the peripheral organs but also in the central nervous system during development and 
adulthood. In general, glucocorticoids are considered anti-inflammatory and protective 
agents due to their ability to inhibit gene expression of pro-inflammatory mediators 
and other possible damaging molecules. Nonetheless, recent studies have uncovered 
situations in which these hormones can act as pro-inflammatory agents depending on 
the dose, chronicity of exposure, and the structure/organ analyzed. In this review, we will 
provide an overview of the conditions under which these phenomena occur, a discussion 
that will serve as a basis for exploring the mechanistic foundation of glucocorticoids 
pro-inflammatory gene regulation in the brain.
Keywords: glucocorticoids, glucocorticoids receptors, brain, steroid hormones, inflammation, cytokines, 
pro-inflammatory
inTRODUCTiOn
inflammation and Glucocorticoids
Inflammation is described as a response to infection or injury. The cells of innate immunity, such 
as neutrophils and macrophages in the periphery (1) and microglia (2) in the CNS, express recep-
tors called pattern recognition receptors (PRRs) (3, 4) that are able to recognize parts of conserved 
evolutionarily microbial molecules called pathogen-associated molecular patterns (PAMPs) (5). 
They also can recognize endogenous molecules called alarmins or danger-associated molecular 
patterns (DAMPs), which are host-derived proteins released from cells following tissue injury (1, 6). 
It has been greatly demonstrated that chronic inflammation is associated with several pathologies, 
such as obesity (7), cardiovascular diseases (8), rheumatoid arthritis (9), inflammatory bowel disease 
(10, 11), asthma (12, 13), diabetes (14, 15), neurodegenerative diseases (16), and cancer (17). These 
diseases are mostly characterized by a dysregulated inflammatory response, when the normally 
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protective role of inflammation becomes detrimental as the 
response becomes excessive in magnitude or duration.
Glucocorticoids (GCs, cortisol in primates and corticoster-
one – CORT – in rodents) are steroid hormones that essentially 
regulate a variety of physiological processes, including embryonic 
development, metabolism of carbohydrates, lipids, and proteins, 
the stress response, and the resolution of inflammation (6). GCs 
have potent anti-inflammatory and immunosuppressive action, 
reflecting the fact that they are the most widely prescribed drug 
for the treatment of a variety of inflammatory and autoimmune 
diseases (18). They are mainly synthetized in the suprarenal cortex 
as result of the activation of the hypothalamic–pituitary–adrenal 
axis (HPA axis).
In general, GCs are considered anti-inflammatory and 
protective agents, since they inhibit gene expression of pro-
inflammatory mediators and other possible damaging molecules, 
e.g., reactive oxygen species (ROS), in peripheral organs and in 
the CNS. Despite the primary anti-inflammatory actions of GCs 
to resolve inflammatory process and restore homeostasis, it is 
becoming increasingly common studies, suggesting that GCs 
are not uniformly anti-inflammatory and in some cases may 
even increase certain parameters of the inflammatory response, 
mainly in the CNS (19), depending on the dose, chronicity of 
exposure, and structure/organ analyzed.
In this review, we will provide an overview of the conditions 
under which these phenomena occur, a discussion that will serve 
as a basis for exploring the mechanistic foundation of glucocorti-
coid potentiation of pro-inflammatory gene regulation.
Glucocorticoid Receptor
As other steroids, GCs are lipophilic molecules that easily reach 
the cytoplasm of target cells via peripheral circulation, where they 
are bound to carrier proteins and then diffuse promptly through 
cell membranes to modulate gene transcription through their two 
different nuclear receptors: the mineralocorticoid receptor (MR) 
or the glucocorticoid receptor (GR) (20, 21). The affinity of CORT 
for MR is 10-fold higher than for GR, consequently, MR is heavily 
occupied by basal CORT levels, being mainly responsible for the 
physiological effects of GCs, and GR is only heavily occupied 
during pharmacological levels of CORT or during peak secretion 
of this hormone, commonly observed in stressful situations (22).
The GR molecular structure consists of three functional 
domains: (1) the N-terminal amino domain (NTD) that contains 
one of the main transactivation domain, called the activation 
function 1 (AF1). This domain is functionally important, since 
it is required for transcriptional activity of steroid hormones; (2) 
the DNA-binding domain (DBD), which binds to the glucocor-
ticoid responsive elements (GRE) sites in the promoter region of 
target genes; and (3) ligand-binding domain (LBD) that contains 
the binding domain to glucocorticoids as well as important 
sequences for interaction with coregulators, whether coactivators 
and/or corepressors (23).
Two human isoforms of GR have been identified, GRα and 
GRβ, which are originated by alternative splicing of the primary 
transcript GR. The GRα is the predominant isoform of the recep-
tor, and it is the one that transduces GCs signal (23). The GRβ 
differs from GRα in the carboxy terminal sequence, where the last 
50 amino acids are replaced by a sequence of 15 non-homologous 
amino acids, making GRβ non-responsive to GCs (23, 24), with 
no transcription of target genes when GCs binds to GRβ through 
a mechanism involving the formation of heterodimers GRα–GRβ 
(23). The GRβ has been described in some cells, especially inflam-
matory cells, such as lymphocytes and macrophages, and related 
with GCs resistance in diseases, such as asthma (12) and chronic 
lymphocytic leukemia (25). Recently, GRβ was reported in liver 
of mice (26) and rats (27) with a role in metabolism control by 
insulin.
Glucocorticoid receptor isoforms are subject to various 
posttranslational alterations that further modulate receptor 
activity. After binding to GC, the conformational changes 
make them susceptible to modifications, i.e., phosphorylation, 
acetylation, ubiquitination, and sumoylation (23, 28–30), 
which influence DNA-binding complex force, affecting tran-
scription and selection of genes regulated by this complex. The 
multiple phosphorylation events affecting GR NTD lead to 
changes in the spectrum of GR target genes and is thought to 
influence both transcriptional activity and nuclear trafficking 
(23, 30–32).
In conclusion, gene regulation by GCs is complex. The 
sequence of the DNA-binding site influences the conformation 
of the GC–GR, leading to different patterns of gene expression, 
including the pro-inflammatory ones. In addition, the recruit-
ment of the GC–GR and their regulatory elements, as coactiva-
tors and RNA polymerase II to DNA binding, is also dependent 
on the existence of accessible chromatin, which appears to be cell 
type specific (29).
Glucocorticoid Signal Transduction
Upon reaching the target tissue, GCs bind to nuclear receptors, 
classical GRs, in the cytoplasm (33). GR binding promotes their 
release from a multiprotein complex composed by chaperones, 
e.g., Hsp70, Hsp90, p23, and immunophilins (FKBP51, FKBP52) 
(18, 30), allowing the GC–GR complex to interact with other 
cytosolic proteins, or in most cases, to translocate to the nucleus 
as a result of the exposure of a nuclear localization domain 
(18). Upon ligation and translocation, GR dimerizes and binds 
to DNA at palindromic GRE sites, activating the promoter as a 
transcription factor (transactivation), altering gene expression 
of various proteins. The GRE structure is not exclusive for GR 
binding, as it is also common for other nuclear receptors, such 
as MR, progesterone, and androgen receptors. For that reason, 
it is referred from some authors as hormonal response elements 
(HREs) rather than GRE (34).
The GC–GR complex also acts without dimerization, as a 
monomeric complex, and binds to DNA together with other 
transcription factor, in this way cooperatively enhancing gene 
expression (composite transactivation). In addition, the GC–GR 
complex can also physically interact with transcription factors 
without interacting with DNA itself, thereby inhibiting the 
transcription factor and repressing transcription. This is the 
predominant transrepression mechanism and is called tethering; 
it is the mechanism responsible to inhibit the pro-inflammatory 
transcription factors, NFκB (35, 36) and activator protein 1 (AP-
1) (37), and also other transcription factors, such as CREB (38), 
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accounting for the anti-inflammatory and immunosuppressive 
GCs effects.
In addition to the GR-mediated genomic mechanisms, several 
rapid non-genomic pathways have also been reported. According 
to them, GCs can have direct effects on cell membrane, interacting 
with membrane GR (mGR), as reported in human lymphocytes 
and monocytes (39), and in skeletal muscle fibers in mice (40). 
GCs can also interact with classical GRs targeting signaling pro-
teins, such as kinases, and/or with classic GRs translocating into 
the mitochondria, one of the probable mechanisms of apoptosis 
induced by GC–GR complex on T cells (41–43). These pathways 
can result in the induction of downstream signaling cascades, 
changes in cytoplasmic calcium, sodium, or potassium concen-
trations, and increase in mitochondrial production of ROS (21, 
34, 44).
The Pro-inflammatory Glucocorticoid 
effects
The evidence supporting the pro-inflammatory GC effects is very 
robust and suggests that they occur in specific and very intricate 
situations. Timing, concentration, and duration of GC exposure 
are all critical in determining whether these hormones will be 
immunoactivator or immunosuppressor, but the specific situa-
tions leading to each outcome are not well documented.
Munhoz et al. (45, 46) have shown that chronic unpredictable 
stress (CUS), which chronically augment plasma CORT, and 
mid-to-high levels of CORT enhance the LPS-induced NFκB 
activation as well as the expression of pro-inflammatory genes 
(iNOS, IL-1β, TNF-α), while decrease the expression of classi-
cal anti-inflammatory ones (IL-1ra, IL-10, and MKP-1) in the 
frontal cortex and in a lesser extent in the hippocampus of rats. 
These pro-inflammatory GCs effects were region-dependent and 
GR-mediated, since they were not evident in the hypothalamus 
or heart of rats, and the pretreatment with the RU486 reversed 
them (45, 46).
Microglia are an important player in the GC endangerment 
to neurons. Sorrells et al. (47) have shown that the concurrent 
treatment with minocycline, a microglia inhibitor, but not 
indomethacin, a non-steroid anti-inflammatory drug, prevented 
GC endangerment in a model of neuronal death using kainic 
acid. High GC levels did not substantially affect the levels of 
the chemokines, CCL2, CINC-1, or baseline NFκB activity, 
but they did suppress mRNA levels of CX3CL1, CX3CR1, and 
CD22 in the hippocampus  –  factors that restrain inflamma-
tory responses  –  while increased by twofold the IL-1β mRNA 
expression (47). In another study, using transgenic mice lacking 
GR expression in myeloid cells (microglia included), the same 
group showed that GC effects on myeloid cells have detrimental 
consequences for neuron survival in a kainic acid and transitory 
MCAO occlusion model (48). Indeed, GCs can activate microglia, 
putting them in a “primed” state (49–51). The primed microglia 
can undergo changes such as cell surface upregulation of recep-
tors (e.g., TLRs and NLRs) (52, 53) and myeloid markers (e.g., 
MHC II) (54, 55), promoting a “sensitized” state without produc-
tion of inflammatory or anti-inflammatory mediators, but, with 
further stimulus, can produce exaggerated levels of inflammatory 
mediators. It has been showed increased plasma  levels of TNFα 
and IL-1β, and IL-1β content in various CNS regions (pituitary, 
hypothalamus, hippocampus, and cerebellum) shortly after the 
LPS challenge (56).
Timing is an important variable to determine the outcome of 
GCs actions. Frank et al. (50, 57) reported that CORT adminis-
tered acutely before an LPS challenge facilitated the inflamma-
tory response to the challenge, both in the periphery and in the 
brain. In contrast, CORT administered after the same immune 
challenge resulted in suppression of the inflammatory response 
(50). They further demonstrated that prior in vivo administration 
of CORT potentiated the pro-inflammatory response of isolated 
hippocampal microglia exposed, ex vivo, to LPS (51), establish-
ing a direct relationship between CORT elevation and sensitizing 
hippocampal microglia.
Corticosterone is also important in the sensitization of micro-
glia in aging. Aged rats, submitted to an immune challenge, show 
potentiated and longer inflammatory response. Such potentiation 
has been associated with impairments in hippocampal synaptic 
plasticity and in contextual and spatial forms of memory (57–59). 
Interestingly, these aged rats exhibited higher corticosterone 
levels in the hippocampus, but not in the plasma, throughout the 
diurnal inactive phase only. Furthermore, the elevated diurnal 
hippocampal CORT was associated with an increased expression 
of hippocampal 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1), the enzyme that catalyzes GCs inactive form, 1-dehy-
drocorticosterone, to the active one, CORT, and to a greater 
hippocampal GR activation, also only in the inactive phase of 
the day. Moreover, nuclear-specific expression of GR during the 
inactive phase was significantly higher in aged rats (59).
Although the molecular mechanism of GC pro-inflammatory 
actions is largely unknown, new players have been set in action. 
GCs upregulate the expression of the TLR2 and TLR4, both 
involved in the recognition of PAMPS and DAMPS and in the 
activation of signaling cascades that lead to the synthesis and 
release of inflammatory mediators (60). In vitro and in vivo stud-
ies have demonstrated that GCs can upregulate TLR2 expression 
by the activation of MAPK phosphatase-1 (MKP-1), which, in 
turn, inhibits p38 MAPK activity, a negative regulator for TLR2. 
The increased expression of TLR2 leads to enhanced cytokine 
expression, such as TNF-α, IL-1β, and IL-8, upon challenge with 
an inflammatory stimulus. In addition, TNF-α and GCs cooper-
ate to stimulate the promoter for TLR2 and potentially TLR4, 
increasing receptor expression (57, 61, 62) (Figures 1A,B).
The scientific literature provides growing information about 
the recently described new class of intracellular PRRs, the nucleo-
tide-binding domain, leucine-rich repeat-containing (NBD-LRR, 
referred as NLRs) (63). Of the several NLRs recognized, NLRP1, 
NLRP3, AIM2, and NLRC4 are able to assemble and form a mul-
tiprotein complex known as the inflammasome. This complex 
regulates the activation of caspase-1 and the subsequent matura-
tion and release of pro-inflammatory cytokines, such as IL-1β 
and IL-18, in response to a wide variety of intracellular PRRs [for 
subject review, see Ref. (64)]. NLRP3 could be involved in GCs 
pro-inflammatory actions, as GCs potentiates the LPS-induced 
pro-inflammatory cytokine IL-1β (45, 46). Indeed, Busillo et al. 
(65) demonstrated that NLRP3 is a GC-responsive gene in 
FiGURe 1 | Glucocorticoid-mediated modulation of pro-inflammatory pathways. (A) LPS binds to TLR4 and activates the MAP kinase pathway, activating 
NFκB and increasing the gene expression of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6). Elevated and prolonged GC exposure increases and potentiates 
the pro-inflammatory response related to MAP kinase–NFκB pathway. (B) GR activation regulates the gene and protein expression of TLR2, which recognizes 
PAMPS. This event recruits intracellular proteins, ultimately leading to the downstream signaling activation of NFκB, increasing the expression of inflammatory 
cytokines, including IL-6, TNF-α, and IL-1β. (C)  GR activation regulates the gene and protein expression of NLRP3, which recognizes DAMPS and regulates the 
immune system response in a mechanism similar to the proposed in (B). Schematic figures based on Ref. (39, 70).
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macrophages, an effect GR-dependent. Glucocorticoid induction 
of NLRP3 sensitizes macrophages to extracellular ATP, which 
results in the secretion of pro-inflammatory cytokines, such as 
IL-1β, TNF-α, and IL-6 (65). Furthermore, GCs have been sug-
gested to induce the expression of the purinergic receptor P2Y2R, 
which once activated, enhances IL-6 secretion by endothelial cells 
in response to ATP (66). Therefore, GC-mediated activation of 
TLR2, NLRP3, P2Y2R, and potentiation of TNF-α- and pro-
inflammatory genes provide a potential mechanism by which 
these hormones exert pro-inflammatory actions (Figure 1C).
In addition, Weber and colleagues reported a new stress-
induced pro-inflammatory mediator, the alarmin high-mobility 
group box-1 protein (HMGB-1) (67). HMGB-1 has been reported 
to be present in the CNS and to play a role in mediating neuro-
inflammatory responses to ischemia and other injuries, such as 
immune disorders and neurodegenerative diseases [extensively 
reviewed in Ref. (68)]. Severe acute stress increases HMGB-1 
protein levels in the hippocampus, specifically in the cytosol 
of hippocampal microglia isolated from severely acute stressed 
rats. NLRP3, IKBα, and NFKB proteins levels are also increased 
immediately after severe acute stress. Interestingly, Box A (a 
HMGB-1 antagonist) pretreatment blocked the stress-induced 
increase in microglial IL-1β, IKBα, and NLRP3 mRNA expression 
in response to a bacterial challenge (67). These results suggest that 
HMGB-1 participates in stress-inducing NLRP3 priming, adding 
another mechanism by which GCs could have pro-inflammatory 
effects in the brain (67, 69).
MineRALOCORTiCOiDS
Aldosterone is the steroidal hormone produced in the cortex 
of suprarenal gland that specifically binds to the MR. Although 
aldosterone is the related ligand of the MR, GCs can also bind 
to this receptor with equivalent affinity. The production and 
secretion of this hormone are majorly triggered in response to 
alterations in blood perfusion, perceived by cells in the juxtaglo-
merular complex. The main goal of this action is to maintain the 
blood pressure in a normal range in terms of control of water 
and electrolyte homeostasis (70). Mineralocorticoids can also 
modulate inflammation. MR expression is observed in cells of 
the immune system and aldosterone has been associated with 
pro-inflammatory immune effects, such as the release of pro-
inflammatory cytokines, generating oxidative stress and inducing 
fibrosis (71).
Clinical studies have demonstrated that MR antagonism in 
cardiovascular diseases can blunt inflammatory damage, an 
important step in the induction of cardiac fibrosis (72). In vitro 
studies, using myeloid murine cells, have suggested an important 
role of mineralocorticoid in inducing changes in macrophages 
phenotype and, therefore, function.
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In response to different inflammatory stimuli, macrophages 
can undergo classical M1 activation (stimulated by TLR ligands 
and IFN-γ) or alternative M2 activation (stimulated by IL-4/
IL-13 cytokines); these states would correspond to the Th1–Th2 
polarization of T cells [for review, see Ref. (73)]. In this sense, in 
dendritic cells from mice, it was shown that aldosterone induces 
the secretion of IL-6 and TGF-β, two pro-inflammatory cytokines 
necessary for the polarization of the adaptive immune response 
toward a Th17 phenotype, proning the system to autoimmunity 
(74). In peritoneal macrophages, aldosterone treatment promoted 
the activation of M1 macrophages, inducing TNFα, MCP-1, and 
IL12 gene expression, all those prevented by MR antagonism (75).
Regarding molecular mechanisms, it has been suggested that 
aldosterone, through MR, could regulate the expression of several 
genes. Indeed, cytokine promoters contain HREs, which can be 
modulated by GCs and potentially by mineralocorticoids (20). 
Despite it was suggested that ligand–receptor binding to simple 
HRE is enough to induce gene expression, many other proteins 
are able to modulate these interactions, adding specificity to 
gene transcription induced by MR. Also, this interaction could 
be more complex once the HRE also contains binding sites for 
non-receptor factors, the composite HREs (76).
In the brain, MR activation is important to maintain many 
functions of this tissue [for review, see Ref. (77)]. Under patho-
logical conditions, such as cerebral stroke, MR antagonism or 
ablation has been associated with reduction of ischemic area, 
lower markers of remodeling process in cerebral vessels, and 
reduction of microglial/macrophages infiltration and activation, 
with decreased expression of cytokines and chemokines, such 
as IL-1β, IL-6, TNF-α, MCP-1, and MIP-1. It was also reported 
that the MR activation in myeloid cells exacerbates inflamma-
tion and alters the M1/M2 inflammatory response to stroke 
(78). Finally, a study using microglial cells BV-2 reported that 
the stimulation with aldosterone resulted in NFκB activation and 
the nuclear translocation of its p65 subunit, further upregulating 
the expression of IL-6 and TNFr2, reinforcing the evidence of 
pro-inflammatory actions of mineralocorticoids in the brain (79).
COnCLUDinG ReMARKS
Together, these findings suggest that exposure to steroid hormones 
in special conditions can shift the (neuro)immune microenviron-
ment toward a pro-inflammatory state, predisposing certain 
regions of the CNS to a stronger pro-inflammatory response, if 
the organism is exposed to a subsequent challenge. Given the 
clinical implications of the pro-inflammatory steroid hormones 
actions, it is important to emphasize the need for continued basic 
investigations to understand the unexpected capacity of these 
hormones to increase CNS inflammation. Future research must 
be directed at determining how steroid hormones act on differ-
ent cell types and regions to produce such markedly different 
immunomodulatory outcomes.
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